GLP-1 and GLP-3R peptides use a structured lab schedule at baseline, 3 months, 6 months, and annually to protect safety and track results.
Baseline labs define kidney, liver, blood sugar, thyroid, and nutritional status before treatment, which helps flag contraindications and set safety benchmarks.
The 3-month panel targets early blood sugar response and key nutrients like B12 and magnesium that can drop quickly with GI side effects.
Comprehensive 6-month and annual panels reassess lipids, thyroid, kidney function, and nutritional markers to guide dose changes and long-term care.
Schedule a personalized lab review and peptide protocol with the team at Mirror Plastic Surgery so you can begin therapy safely and confidently.
GLP-1 and GLP-3R Lab Monitoring Schedule
The following table shows which labs are checked at each visit and highlights the focused 3-month column, which tracks early glycemic response and GI-related nutrient changes before the full 6-month and annual panels.
Lab Test
Baseline
3 Months
6 Months / Annual
Comprehensive Metabolic Panel (CMP)
✓
✓
✓
HbA1c
✓
✓
✓
Fasting Glucose
✓
✓
✓
Lipid Panel
✓
—
✓
Thyroid Panel (TSH, Free T3, Free T4)
✓
—
✓
Complete Blood Count (CBC)
✓
—
✓
Vitamin B12
✓
✓
✓
Vitamin D (25-OH)
✓
—
✓
Iron Studies (Ferritin, TIBC, Serum Iron)
✓
—
✓
Magnesium
✓
✓
✓
Lipase
✓
If symptomatic
✓
Uric Acid
✓
—
✓
Note: The 3-month column reflects targeted monitoring for early glycemic response and GI-related nutritional depletion. The 6-month panel is typically comprehensive and mirrors the annual schedule for patients in the first year of therapy.
Baseline Labs Before Starting GLP-1 or GLP-3R Therapy
Baseline labs define your metabolic starting point and identify contraindications before the first dose. Each panel serves a clear clinical role.
Comprehensive Metabolic Panel (CMP): Evaluates kidney function (creatinine, BUN, eGFR) and liver enzymes (ALT, AST, ALP). GLP-1 therapies can cause nausea, vomiting, and dehydration, which stress renal tubules, so a pre-treatment eGFR sets a safety baseline.
HbA1c and Fasting Glucose: Confirm glycemic status. Patients with undiagnosed type 2 diabetes need closer glucose monitoring and may follow a different titration plan.
Lipid Panel: Documents cardiovascular risk factors and provides a reference point for tracking changes in LDL and triglycerides during therapy.
Thyroid Panel: GLP-1 receptor agonists carry a class warning regarding thyroid C-cell tumors in rodent models. A baseline TSH and free thyroid hormones screen for pre-existing thyroid issues.
CBC: Screens for baseline anemia, which can worsen if nutritional intake falls during rapid weight loss.
Lipase: Establishes a pre-treatment pancreatic enzyme level for comparison if abdominal symptoms appear later.
Nutritional markers (B12, D, Iron, Magnesium): Reveal existing deficiencies that caloric restriction is likely to deepen.
GLP-3R-specific note: GLP-3R compounds act on additional receptor subtypes beyond GLP-1R. Baseline cardiovascular markers and inflammatory panels (hsCRP) help track broader metabolic indications, including insulin resistance and cardiovascular risk reduction.
The 3-month draw stays focused instead of comprehensive. Its main role is to confirm early glycemic response by checking HbA1c and fasting glucose and to see whether the dose is lowering blood sugar and appetite signals as expected.
Because of the GI effects noted earlier, magnesium and B12 are also checked at 3 months. These nutrients can fall faster than an annual schedule would catch. Lipase is ordered at 3 months only when patients report persistent mid-epigastric pain, nausea that feels different from early adjustment, or back pain that radiates from the abdomen.
The 6-month panel mirrors the annual schedule and returns to a comprehensive view. By this point, most patients have reached a maintenance dose. This timing makes 6 months the ideal moment to reassess lipids, thyroid function, full nutritional status, and kidney function together. Dose changes made at this visit are often the most significant of the first year.
Nutritional Labs During GLP-1 and GLP-3R Therapy
Caloric restriction and reduced appetite during GLP-1 or GLP-3R therapy create predictable nutritional gaps. The following markers need monitoring on a set schedule.
Vitamin B12: Baseline, 3 months, and annually. Lower intake and shifts in gastric acid can impair B12 absorption. Deficiency can cause fatigue, peripheral neuropathy, and cognitive changes, which often mimic other conditions without lab confirmation.
Vitamin D (25-OH): Baseline and annually. Reduced dietary fat can affect absorption of this fat-soluble vitamin. Low vitamin D contributes to bone loss, immune changes, and mood disturbance.
Iron Studies (Ferritin, TIBC, Serum Iron): Baseline and annually. Less red meat and lower overall calories increase iron deficiency risk, especially in premenopausal women.
Magnesium: Baseline, 3 months, and annually. Nausea, vomiting, and diarrhea can deplete magnesium quickly. Low magnesium can trigger muscle cramps, cardiac arrhythmias, and insulin resistance, which work against metabolic goals.
When to Check Lipase on GLP-1s
Lipase is drawn at baseline and again at the 6-month or annual visit as part of routine monitoring. Between those visits, lipase becomes necessary when specific warning symptoms appear.
Red-Flag Symptoms Requiring Immediate Lipase Testing and Clinical Evaluation:
Severe, persistent mid-epigastric or upper abdominal pain lasting more than a few hours
Pain that radiates to the back and does not improve with position changes
Nausea and vomiting that feel out of proportion to the early GI adjustment period (beyond the first 4–6 weeks)
Fever that occurs with abdominal pain
Marked worsening of symptoms after dose increases
These symptoms may indicate pancreatitis. Discontinue the peptide and seek medical evaluation promptly.
The monitoring protocols described above require clinical interpretation and individualized adjustment, which makes experienced practitioner oversight essential.
Meet Ellie Pranckevicius, FNP-BC: Lead Practitioner for Peptide Protocols
Ellie Pranckevicius, FNP-BC, is a board-certified Family Nurse Practitioner who leads peptide therapy and non-surgical aesthetics at Mirror Plastic Surgery. She holds a Bachelor’s in Health Science from Boston University, completed an aesthetics licensure program, and earned both her Bachelor’s and Master’s in Nursing from the University of South Florida.
Ellie Pranckevicius, FNP-BC
Her clinical foundation includes four years in the Neuroscience ICU at Tampa General Hospital, where she managed complex patients with acute metabolic and physiologic instability. That experience directly shapes her approach to GLP-1 and GLP-3R monitoring. Ellie’s combined background in esthetics and advanced nursing practice gives her a clear view of the aesthetic results patients want and the clinical science required to reach those goals safely.
GLP-1 Receptor Agonists: Peptides that bind to glucagon-like peptide-1 receptors in the pancreas, gut, and brain to reduce appetite, slow gastric emptying, and improve insulin secretion.
GLP-3R Peptides: A newer class of multi-receptor compounds that engage additional receptor subtypes. Early data suggest broader metabolic benefits with fewer GI side effects and a lower risk of lean muscle loss compared to some earlier GLP-1 formulations.1
Compounding: Preparation of a customized peptide formulation by a licensed compounding pharmacy based on a practitioner’s prescription, which allows individualized dosing not available in standard commercial products.
Batch Testing: Third-party laboratory verification of a compounded peptide’s identity, purity, potency, and sterility. Batch-tested products provide documented proof that the compound matches the label at the stated concentration.
How GLP-1 and GLP-3R Care Works at Mirror Plastic Surgery
At Mirror Plastic Surgery, GLP-1 and GLP-3R therapy follows a clear, stepwise workflow. The process starts with a 30–60 minute consultation with Ellie that covers full medical history, current medications, prior lab results, and specific health goals.
If recent labs are missing or incomplete, Ellie orders the needed baseline panel before starting any protocol. After results are reviewed, she sets a customized dose and titration schedule. Patients receive detailed reconstitution and self-administration instructions, often supported by video demonstrations.
Ongoing support includes direct text access to Ellie, and follow-up lab draws at 3 and 6 months. Dose changes, nutritional supplements, and protocol adjustments are based on lab trends rather than symptoms alone.
Current Trends in GLP-1 and GLP-3R Therapy
The peptide therapy market is moving toward newer-generation GLP-3R formulations as patients and practitioners look for options with fewer GI side effects and a lower risk of lean muscle loss, a documented concern with some first-generation GLP-1 agonists. At the same time, nutritional monitoring is becoming a standard part of GLP-1 care instead of an optional extra.
More practitioners now include B12, iron, and magnesium panels in routine follow-up schedules. Evidence shows that rapid weight loss without nutritional oversight can blunt the metabolic gains these therapies are meant to deliver.1
Important Considerations for Safe Peptide Use
Three factors shape whether peptide therapy stays safe and effective over time.
Batch-tested sourcing: Peptides from suppliers without documented batch testing have unknown purity and potency. Sourcing from reputable compounding providers with third-party verification creates a quality foundation that supports predictable dosing and safety.
Medical supervision for dose titration: Once product quality is confirmed, individualized dosing becomes the next key variable. Dose escalation without lab-guided oversight raises the risk of side effects and lowers the chance of reaching an effective maintenance dose efficiently.
Individualized maintenance schedules: Annual monitoring sets the minimum standard. Patients with kidney impairment, thyroid disease, or significant nutritional deficiencies at baseline may need more frequent labs during the first year to catch problems early.
Risks, Limitations, and Common Challenges
Kidney stress: Persistent nausea, vomiting, or diarrhea can cause dehydration that lowers eGFR, especially in patients with borderline kidney function at baseline.
Variable patient response: Genetics, gut microbiome, baseline metabolic health, and adherence to dietary guidance all influence outcomes. These differences make the individualized monitoring schedules discussed earlier essential rather than optional.
Regulatory status: Many compounded GLP-1 and GLP-3R peptides are not FDA-approved products. This does not prevent clinical use, but it shifts quality assurance onto the provider’s sourcing and supervision practices.
Correcting Common GLP-1 and GLP-3R Misconceptions
“GLP-1s are only for weight loss.” GLP-1 and GLP-3R peptides also address insulin resistance, cardiovascular risk factors, and inflammatory metabolic pathways. Weight reduction is one outcome, not the only indication.1
“Labs are only needed once, at the start.” Metabolic markers change throughout therapy. A single baseline draw cannot capture nutritional depletion, renal shifts, or glycemic normalization that develop over months.
“All GLP-1 formulations carry the same side-effect profile.” GLP-3R compounds engage receptor subtypes beyond GLP-1R, and early experience suggests differences in GI tolerability and muscle preservation compared to some first-generation GLP-1 agonists. Formulation choice should match patient history and goals.
Frequently Asked Questions
What labs are needed before starting a GLP-1 or GLP-3R peptide? A comprehensive metabolic panel, HbA1c, fasting glucose, lipid panel, thyroid panel, CBC, lipase, vitamin B12, vitamin D, iron studies, and magnesium form the standard baseline set. These tests define kidney and liver function, glycemic status, cardiovascular risk, thyroid health, and nutritional starting points before any dose. If you have recent labs from another provider, Ellie reviews them during your consultation and orders only what is still needed.
How often do I need bloodwork while on GLP-1 therapy? The usual schedule includes baseline labs before starting, a targeted draw at 3 months that focuses on glycemic response and key nutritional markers, a comprehensive panel at 6 months, and annual monitoring after that. Patients with kidney disease, thyroid disorders, or notable nutritional deficiencies at baseline may need more frequent testing during the first year.
Is it safe to use GLP-1 or GLP-3R peptides without medical supervision? Using compounded peptides without medical supervision carries real risk. Without baseline labs, contraindications such as impaired kidney function or undiagnosed thyroid disease remain hidden. Without follow-up monitoring, nutritional deficiencies, renal stress, and poor dosing go unnoticed. Peptides bought online without batch testing also lack verified purity or potency. Supervised, lab-guided care remains the evidence-based standard for safe and effective use.
What is the difference between GLP-1 and GLP-3R peptides? GLP-1 receptor agonists bind mainly to the GLP-1 receptor to regulate appetite, glucose, and gastric emptying. GLP-3R compounds engage additional receptor subtypes, which may provide broader metabolic benefits, fewer GI side effects, and a lower chance of lean muscle loss for some patients.1 The right choice depends on your health history, goals, and lab results and is decided during your consultation with Ellie.
What happens if my labs show an abnormality during therapy? Abnormal results trigger a protocol review rather than automatic discontinuation. Ellie interprets results in the context of your full clinical picture, including symptoms, dose history, dietary changes, and baseline values. Depending on the issue, she may recommend dose reduction, a temporary hold, nutritional supplements, extra targeted testing, or referral to a specialist. This level of interpretation separates supervised concierge care from self-managed peptide use.
Conclusion: Why Structured Lab Monitoring Matters
Structured lab monitoring at baseline, 3 months, 6 months, and annually keeps GLP-1 and GLP-3R therapy both safe and effective over time. Kidney function, glycemic response, nutritional status, and pancreatic enzyme levels all shift during active treatment, and those shifts require clinical interpretation rather than guesswork.
At Mirror Plastic Surgery, Ellie Pranckevicius leads every peptide protocol with the individualized, evidence-informed oversight she developed through years of critical-care and advanced-practice nursing. This concierge model uses lab results to guide decisions, relies on verified sourcing, and gives patients direct access to their provider throughout the process.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
